Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma

Daniel M. Geynisman; William S. John; Taavy A. Miller; Parisa Asgarisabet; Sarah B. Guttenplan; Xin Yin; Kristin M. Zimmerman Savill; Lindsay Mcallister; Lisa Rosenblatt

doi:10.1093/oncolo/oyae354

Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma

Daniel M. Geynisman
, William S. John
, Taavy A. Miller
, Parisa Asgarisabet
, Sarah B. Guttenplan
, Xin Yin
, Kristin M. Zimmerman Savill
, Lindsay Mcallister
, Lisa Rosenblatt

Cardinal Health , Dublin, OH
Bristol Myers Squibb , Princeton, NJ

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

BACKGROUND: Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.

METHODS: We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.

RESULTS: Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2% versus 21.3%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.

CONCLUSIONS: These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.

Original language	English
Article number	oyae354
Number of pages	5
Journal	Oncologist
Volume	30
Issue number	7
Early online date	Nov 19 2024
DOIs	https://doi.org/10.1093/oncolo/oyae354 https://doi.org/10.1093/oncolo/oyae354
State	Published - Jul 1 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Ethnic and racial minorities
Nivolumab
Pembrolizumab
Renal cell carcinoma
Tyrosine kinase inhibitors
Kidney Neoplasms/drug therapy
Black or African American
Humans
Middle Aged
Male
Treatment Outcome
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
White
Antibodies, Monoclonal, Humanized/administration & dosage
Female
Carcinoma, Renal Cell/drug therapy
Aged
Retrospective Studies

Access to Document

Cite this

@article{0fcd0ac59a3a471da83a282004a90d5d,

title = "Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma",

abstract = "BACKGROUND: Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.METHODS: We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.RESULTS: Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2\% versus 21.3\%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.CONCLUSIONS: These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.",

keywords = "Ethnic and racial minorities, Nivolumab, Pembrolizumab, Renal cell carcinoma, Tyrosine kinase inhibitors, Kidney Neoplasms/drug therapy, Black or African American, Humans, Middle Aged, Male, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, White, Antibodies, Monoclonal, Humanized/administration \& dosage, Female, Carcinoma, Renal Cell/drug therapy, Aged, Retrospective Studies",

author = "Geynisman, \{Daniel M.\} and John, \{William S.\} and Miller, \{Taavy A.\} and Parisa Asgarisabet and Guttenplan, \{Sarah B.\} and Xin Yin and Savill, \{Kristin M. Zimmerman\} and Lindsay Mcallister and Lisa Rosenblatt",

note = "{\textcopyright} The Author(s) 2024. Published by Oxford University Press.",

year = "2025",

month = jul,

day = "1",

doi = "10.1093/oncolo/oyae354",

language = "English",

volume = "30",

journal = "Oncologist",

issn = "1083-7159",

publisher = "Oxford University Press",

number = "7",

}

TY - JOUR

T1 - Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma

AU - Geynisman, Daniel M.

AU - John, William S.

AU - Miller, Taavy A.

AU - Asgarisabet, Parisa

AU - Guttenplan, Sarah B.

AU - Yin, Xin

AU - Savill, Kristin M. Zimmerman

AU - Mcallister, Lindsay

AU - Rosenblatt, Lisa

N1 - © The Author(s) 2024. Published by Oxford University Press.

PY - 2025/7/1

Y1 - 2025/7/1

N2 - BACKGROUND: Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.METHODS: We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.RESULTS: Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2% versus 21.3%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.CONCLUSIONS: These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.

AB - BACKGROUND: Given the historical underrepresentation of racial minorities in clinical trials, little is known about racial differences in outcomes of first-line therapies for advanced renal cell carcinoma (aRCC). This study described patient characteristics and clinical outcomes of first-line therapies for aRCC, including nivolumab + ipilimumab, pembrolizumab + axitinib, and tyrosine kinase inhibitors, by race in the real-world setting.METHODS: We conducted a retrospective medical chart review of patients with intermediate/poor-risk clear-cell aRCC. Treating physicians abstracted patient data from electronic medical charts.RESULTS: Among 346 patients with intermediate/poor-risk aRCC, a higher proportion of African-American/Black (n = 78) versus White (n = 268) patients had poorer baseline functional performance (ECOG-PS ≥ 2: 37.2% versus 21.3%). African-American/Black patients trended toward numerically lower overall response rates and shorter overall survival for nivolumab + ipilimumab or pembrolizumab + axitinib than White patients.CONCLUSIONS: These findings provide important insights into racial differences in first-line aRCC treatment outcomes within real-world settings. Additional research with larger sample sizes is warranted.

KW - Ethnic and racial minorities

KW - Nivolumab

KW - Pembrolizumab

KW - Renal cell carcinoma

KW - Tyrosine kinase inhibitors

KW - Kidney Neoplasms/drug therapy

KW - Black or African American

KW - Humans

KW - Middle Aged

KW - Male

KW - Treatment Outcome

KW - Antineoplastic Combined Chemotherapy Protocols/therapeutic use

KW - White

KW - Antibodies, Monoclonal, Humanized/administration & dosage

KW - Female

KW - Carcinoma, Renal Cell/drug therapy

KW - Aged

KW - Retrospective Studies

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:001380474100001&DestLinkType=FullRecord&DestApp=WOS_CPL

U2 - 10.1093/oncolo/oyae354

DO - 10.1093/oncolo/oyae354

M3 - Article

C2 - 39703163

SN - 1083-7159

VL - 30

JO - Oncologist

JF - Oncologist

IS - 7

M1 - oyae354

ER -

Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Research in the Area of Carcinomas Reported from Fox Chase Cancer Center (Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma)

Cite this

Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Press/Media

Research in the Area of Carcinomas Reported from Fox Chase Cancer Center (Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma)

Cite this